Overview
End-to-end generative AI drug discovery from target identification to clinical trials.
Details
Insilico’s Pharma.AI platform (PandaOmics, Chemistry42, InClinico) covers target discovery, generative chemistry, and trial outcome prediction. Multiple AI-discovered drugs are in clinical trials including INS018_055 for IPF.